ORIGINAL RESEARCH article
Front. Med.
Sec. Hematology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1619750
This article is part of the Research TopicAddressing Cancer in Children, Adolescents, and Young Adults in Low- and Middle-Income Countries: Challenges and Opportunities for Improved OutcomesView all 4 articles
Global Burden of Childhood Burkitt Lymphoma (1990–2021): Epidemiological Trends, Regional Disparities, and Projections for 2035 from the Global Burden of Disease Study
Provisionally accepted
- 1Department of Cardiology, Yan’an Hospital, Kunming Medical University, Kunming, China
- 2Department of Ultrasound Medicine, Kunming Maternal and Child Health Hospital, Kunming, Yunnan Province, China, kunming, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background Burkitt lymphoma (BL) is a highly aggressive pediatric B-cell lymphoma with marked geographic heterogeneity. Up-to-date global estimates are needed to inform prevention and care. Methods We analyzed Global Burden of Disease (GBD) 2021 data to estimate incidence, mortality, and disability-adjusted life years (DALYs) for childhood BL (0–14 years) from 1990–2021 across 204 countries/territories, stratified by sex, age, region, and Sociodemographic Index (SDI). Trends were summarized using joinpoint annual percent change and estimated annual percentage change (EAPC). Bayesian age– period–cohort models projected the burden to 2035. Findings In 2021, there were 4,083 incident BL cases globally (95% uncertainty interval [UI] 2,688–5,171). The global incidence rate was 0.20 per 100,000 (95% UI 0.13–0.26) versus 0.16 per 100,000 (95% UI 0.10–0.23) in 1990. Burden varied substantially by development level: the low-SDI region had the highest incidence rate (0.44 per 100,000, 95% UI 0.26–0.59), mortality rate (0.43 per 100,000, 95% UI 0.25–0.58), and DALY rate (36.19 per 100,000, 95% UI 21.00–48.64). High-SDI regions showed lower mortality rates and evidence of declines, consistent with broader access to timely diagnosis, multi-agent chemotherapy, and supportive care. By 2035, the incidence rate is expected to reach 0.15 (95%CI 0.11-0.19) per 100,000, the mortality rate to 0.10 (95%CI 0.07-0.13) per 100,000, and the DALY rate to 8.21 (95%CI 5.98-10.43) per 100,000. Interpretation Global BL rates appear broadly stable, with pronounced inequities concentrated in low-SDI settings. Apparent improvements are heterogeneous, not universal, and are most evident in high-SDI regions where treatment and supportive care are widely available. Projections to 2035 suggest modest declines in global rates, contingent on sustained malaria control and expanded access to diagnosis and curative therapy in high-burden regions. Targeted investments linking infection control with pediatric oncology capacity are required to reduce the global burden of childhood BL.
Keywords: Burkitt lymphoma (BL), Children, Global Burden of Disease (GBD) 2021, Incidence, DALYs, Mortality
Received: 28 Apr 2025; Accepted: 08 Sep 2025.
Copyright: © 2025 Ma, Li and Jia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Fan Jia, Department of Cardiology, Yan’an Hospital, Kunming Medical University, Kunming, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.